CORT - Corcept Therapeutics Inc Stock Price, Fair Value and News

28.11USD+0.57 (+2.07%)Market Closed

Market Summary

USD28.11+0.57

Market Closed

2.07%

CORT Alerts

1 major insider sales recently.

Big jump in Revenue (Y/Y)
Big jump in Earnings (Y/Y)

CORT Stock Price

View Fullscreen

CORT RSI Chart

CORT Valuation

Market Cap

2.9B

Price/Earnings (Trailing)

24.8

Price/Sales (Trailing)

5.59

EV/EBITDA

19.61

Price/Free Cashflow

23.47

CORT Price/Sales (Trailing)

CORT Profitability

Operating Margin

99.74%

EBT Margin

26.95%

Return on Equity

21.54%

Return on Assets

17.99%

Free Cashflow Yield

4.26%

CORT Fundamentals

CORT Revenue

Revenue (TTM)

523.5M

Rev. Growth (Yr)

38.95%

Rev. Growth (Qtr)

8.42%

CORT Earnings

Earnings (TTM)

118.0M

Earnings Growth (Yr)

74.83%

Earnings Growth (Qtr)

-11.46%

Breaking Down CORT Revenue

Last 7 days

4.0%

Last 30 days

22.2%

Last 90 days

23.8%

Trailing 12 Months

16.9%

How does CORT drawdown profile look like?

CORT Financial Health

Current Ratio

5.18

CORT Investor Care

Shares Dilution (1Y)

2.49%

Diluted EPS (TTM)

1.06

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	523.5M	0	0	0
2023	413.8M	428.2M	450.0M	482.4M
2022	380.2M	392.0M	397.6M	401.9M
2021	340.1M	343.1M	352.9M	366.0M
2020	334.9M	351.2M	356.0M	353.9M
2019	258.4M	268.4M	285.4M	306.5M
2018	189.3M	216.0M	237.7M	251.2M
2017	92.9M	108.7M	129.7M	159.2M
2016	56.2M	64.0M	72.5M	81.3M
2015	32.2M	38.4M	44.3M	50.3M
2014	13.0M	17.0M	21.7M	26.6M
2013	5.0M	6.0M	7.6M	10.4M
2012	2.4M	2.7M	3.0M	3.3M
2011	0	0	1.8M	2.1M
2010	0	566.0K	1.0M	1.5M
2009	0	0	0	101.0K

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Corcept Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 02, 2024	lyon joseph douglas	sold	-281,580	26.00	-10,830	see remarks
May 02, 2024	lyon joseph douglas	acquired	122,920	11.35	10,830	see remarks
May 01, 2024	swisher daniel n jr	sold	-50,798	23.09	-2,200	-
May 01, 2024	swisher daniel n jr	acquired	12,892	5.86	2,200	-
Apr 10, 2024	mahoney david l	sold (taxes)	-52,217	23.8	-2,194	-
Apr 10, 2024	mahoney david l	sold	-	-	-27,806	-
Apr 10, 2024	mahoney david l	acquired	52,200	1.74	30,000	-
Apr 10, 2024	mahoney david l	acquired	-	-	27,806	-
Apr 04, 2024	lyon joseph douglas	sold	-141,524	26.0011	-5,443	see remarks
Apr 04, 2024	lyon joseph douglas	acquired	61,778	11.35	5,443	see remarks

Which funds bought or sold CORT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	HANCOCK WHITNEY CORP	added	130	305,165	692,650	0.02%
May 16, 2024	Ancora Advisors LLC	new	-	362,434	362,434	0.01%
May 16, 2024	COMERICA BANK	reduced	-12.51	-388,942	821,069	-%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-80.33	-2,509,700	451,758	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-4.52	-768,196	2,191,710	-%
May 15, 2024	Hudson Bay Capital Management LP	new	-	1,198,260	1,198,260	0.01%
May 15, 2024	VOLORIDGE INVESTMENT MANAGEMENT, LLC	added	88.79	8,250,730	26,026,900	0.10%
May 15, 2024	Cipher Capital LP	sold off	-100	-380,633	-	-%
May 15, 2024	ALGERT GLOBAL LLC	sold off	-100	-3,966,000	-	-%
May 15, 2024	MARSHALL WACE, LLP	new	-	2,481,190	2,481,190	-%

Are Funds Buying or Selling CORT?

Are funds buying CORT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CORT

No. of Funds

Unveiling Corcept Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 27, 2024	ingalls & snyder llc	8.0%	8,262,476	SC 13G/A
Feb 14, 2024	baker g leonard jr	5.3%	5,512,696	SC 13G/A
Feb 13, 2024	renaissance technologies llc	6.52%	6,725,871	SC 13G/A
Feb 13, 2024	vanguard group inc	9.25%	9,537,532	SC 13G/A
Feb 12, 2024	belanoff joseph k	6.1%	6,581,918	SC 13G/A
Jan 22, 2024	blackrock inc.	15.9%	16,407,696	SC 13G/A
Feb 17, 2023	ingalls & snyder llc	6.6%	7,090,370	SC 13G/A
Feb 15, 2023	belanoff joseph k	5.5%	6,081,918	SC 13G/A
Feb 14, 2023	baker g leonard jr	5.1%	5,485,196	SC 13G/A
Feb 13, 2023	renaissance technologies llc	6.77%	7,288,871	SC 13G/A

Recent SEC filings of Corcept Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 15, 2024	4	Insider Trading
May 13, 2024	144	Notice of Insider Sale Intent
May 13, 2024	4	Insider Trading
May 09, 2024	144	Notice of Insider Sale Intent
May 06, 2024	4	Insider Trading
May 03, 2024	4	Insider Trading
May 01, 2024	10-Q	Quarterly Report
May 01, 2024	144	Notice of Insider Sale Intent
May 01, 2024	8-K	Current Report
Apr 18, 2024	DEFA14A	DEFA14A

Peers (Alternatives to Corcept Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Corcept Therapeutics Inc News

Latest updates

Corcept Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	8.4%	147	135	124	118	106	103	102	103	94.00	99.00	96.00	92.00	79.00	86.00	86.00	89.00	93.00	88.00	82.00	72.00	65.00
Costs and Expenses	13.1%	117	104	92.00	88.00	91.00	81.00	70.00	72.00	67.00	62.00	60.00	60.00	60.00	55.00	62.00	53.00	56.00	53.00	49.00	48.00	46.00
S&GA Expenses	19.3%	56.00	47.00	45.00	43.00	49.00	42.00	35.00	38.00	38.00	32.00	31.00	30.00	30.00	26.00	27.00	26.00	28.00	27.00	24.00	25.00	24.00
R&D Expenses	6.9%	59.00	55.00	46.00	43.00	41.00	37.00	33.00	33.00	28.00	29.00	28.00	28.00	29.00	28.00	34.00	26.00	26.00	24.00	23.00	22.00	20.00
EBITDA Margin	4.3%	0.27*	0.26*	0.25*	0.26*	0.26*	0.29*	0.33*	0.33*	0.35*	0.34*	0.34*	0.32*	-	-	-	-	-	-	-	-	-
Income Taxes	33.5%	7.00	5.00	5.00	5.00	3.00	8.00	-1.60	5.00	4.00	5.00	6.00	6.00	-3.55	5.00	4.00	8.00	9.00	7.00	8.00	6.00	2.00
Earnings Before Taxes	-4.9%	35.00	37.00	36.00	33.00	18.00	24.00	33.00	32.00	27.00	37.00	36.00	32.00	20.00	31.00	25.00	36.00	39.00	36.00	34.00	26.00	20.00
EBT Margin	4.4%	0.27*	0.26*	0.25*	0.25*	0.26*	0.29*	0.32*	0.34*	0.35*	0.34*	0.34*	0.32*	-	-	-	-	-	-	-	-	-
Net Income	-11.5%	28.00	31.00	31.00	28.00	16.00	17.00	35.00	27.00	23.00	32.00	30.00	27.00	23.00	26.00	22.00	28.00	30.00	29.00	26.00	20.00	18.00
Net Income Margin	2.5%	0.23*	0.22*	0.20*	0.22*	0.23*	0.25*	0.29*	0.29*	0.29*	0.31*	0.30*	0.28*	-	-	-	-	-	-	-	-	-
Free Cashflow	303.5%	24.00	6.00	53.00	42.00	26.00	33.00	33.00	18.00	35.00	49.00	49.00	44.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	5.5%	656	622	594	525	618	583	533	496	468	424	585	568	552	572	534	498	445	412	367	329	320
Current Assets	9.8%	503	459	432	433	534	499	452	419	388	266	402	411	410	479	463	438	345	307	267	233	217
Cash Equivalents	10.5%	150	136	112	172	300	66.00	50.00	35.00	62.00	78.00	95.00	95.00	52.00	76.00	31.00	59.00	84.00	31.00	45.00	58.00	50.00
Inventory	-7.0%	7.00	8.00	8.00	7.00	6.00	6.00	6.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00
Net PPE	-34.9%	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	-5.9%	108	115	132	103	88.00	82.00	60.00	54.00	60.00	48.00	45.00	46.00	42.00	48.00	44.00	44.00	36.00	41.00	33.00	31.00	34.00
Current Liabilities	-7.0%	97.00	105	122	93.00	79.00	72.00	53.00	49.00	57.00	48.00	45.00	45.00	41.00	47.00	43.00	42.00	34.00	39.00	32.00	30.00	34.00
Shareholder's Equity	8.1%	548	507	462	422	530	502	473	442	408	376	540	523	511	523	490	454	409	371	334	298	286
Retained Earnings	6.9%	430	403	371	340	312	296	280	245	218	195	163	132	106	82.00	56.00	35.00	7.00	-23.55	-52.94	-79.28	-99.46
Additional Paid-In Capital	2.7%	758	739	722	696	680	662	649	626	609	591	571	554	536	516	496	482	466	457	447	437	427
Shares Outstanding	-0.6%	103	103	102	105	108	108	107	106	106	116	116	117	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	1,827	-	-	-	2,058	-	-	-	2,122	-	-	-	1,633	-	-	-	1,071	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	303.5%	23,756	5,887	52,909	42,286	25,957	33,388	33,648	18,040	35,247	49,427	48,704	44,339	25,422	35,071	30,444	53,186	33,269	48,454	38,427	25,555	23,681
Share Based Compensation	1.4%	13,249	13,065	12,876	11,858	11,141	10,521	10,554	10,606	10,761	10,810	10,952	11,068	10,101	8,430	8,702	8,489	7,918	7,610	7,271	7,736	6,696
Cashflow From Investing	-152.7%	-9,014	17,098	-109,570	-24,097	207,475	-17,241	-4,790	-41,800	-50,496	140,471	-25,803	24,742	-3,284	11,220	-64,273	-85,944	19,734	-61,989	-54,316	-1,156	-367
Cashflow From Financing	-170.9%	-543	766	-3,916	-145,754	181	-61.00	-13,961	-2,756	-506	-206,969	-23,643	-26,032	-45,947	-661	5,866	6,804	205	-144	2,696	-15,908	-15,289
Buy Backs	-	476	-	-	145,428	-	-	-	-	-	-	25,774	29,170	33,541	9,670	-	-	275	-	-	17,420	13,555

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CORT Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Statement of Comprehensive Income [Abstract]
Product revenue, net	$ 146,808	$ 105,654
Operating expenses:
Cost of sales	2,535	1,386
Research and development	58,505	40,851
Selling, general and administrative	56,268	48,564
Total operating expenses	117,308	90,801
Income from operations	29,500	14,853
Interest and other income	5,493	3,581
Income before income taxes	34,993	18,434
Income tax expense	(7,231)	(2,555)
Net income	27,762	15,879
Net income attributable to common stockholders, basic	27,514	15,807
Net income attributable to common stockholders, diluted	$ 27,514	$ 15,807
Basic net income per share (in dollars per share)	$ 0.27	$ 0.15
Diluted net income per share (in dollars per share)	$ 0.25	$ 0.14
Weighted-average shares outstanding used in computing net income per common share
Basic (in shares)	102,791	107,885
Diluted (in shares)	109,915	115,425

CORT Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 149,750	$ 135,551
Short-term marketable securities	261,011	232,670
Trade receivables, net of allowances	61,518	41,123
Insurance recovery receivable related to Melucci litigation (Note 4)	0	14,000
Inventory	7,190	7,730
Prepaid expenses and other current assets	23,898	27,562
Total current assets	503,367	458,636
Strategic inventory	7,846	8,244
Operating lease right-of-use asset	61	120
Property and equipment, net	127	195
Long-term marketable securities	40,276	57,176
Other assets	6,388	6,541
Deferred tax assets, net	97,870	90,605
Total assets	655,935	621,517
Current liabilities:
Accounts payable	12,557	17,396
Accrued research and development expenses	24,825	21,330
Accrued and other liabilities	59,744	51,628
Accrued settlement related to Melucci litigation (Note 4)	0	14,000
Short-term operating lease liability	76	151
Total current liabilities	97,202	104,505
Long-term accrued income taxes payable	10,869	10,307
Total liabilities	108,071	114,812
Commitments and contingencies (Note 4)
Stockholders’ equity:
Preferred stock	0	0
Common stock	133	133
Treasury stock	(641,059)	(635,078)
Additional paid-in capital	758,244	738,515
Accumulated other comprehensive income	258	609
Retained earnings	430,288	402,526
Total stockholders’ equity	547,864	506,705
Total liabilities and stockholders’ equity	$ 655,935	$ 621,517

About Corcept Therapeutics Inc

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe metabolic, oncologic, endocrine, and neurological disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. It is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

CEO	Dr. Joseph K. Belanoff M.D.
WEBSITE	corcept.com
INDUSTRY	Biotechnology
EMPLOYEES	299

Corcept Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Corcept Therapeutics Inc? What does CORT stand for in stocks?

CORT is the stock ticker symbol of Corcept Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Corcept Therapeutics Inc (CORT)?

As of Fri May 17 2024, market cap of Corcept Therapeutics Inc is 2.93 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CORT stock?

You can check CORT's fair value in chart for subscribers.

What is the fair value of CORT stock?

You can check CORT's fair value in chart for subscribers. The fair value of Corcept Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Corcept Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CORT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Corcept Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether CORT is over valued or under valued. Whether Corcept Therapeutics Inc is cheap or expensive depends on the assumptions which impact Corcept Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CORT.

What is Corcept Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, CORT's PE ratio (Price to Earnings) is 24.8 and Price to Sales (PS) ratio is 5.59. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CORT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Corcept Therapeutics Inc's stock?

In the past 10 years, Corcept Therapeutics Inc has provided 0.306 (multiply by 100 for percentage) rate of return.